Novo Nordisk A/S (NOVO-B.CO)
DKK 771.6
(0.22%)
DKK 771.6
(0.22%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 20.52 Billion DKK | -15.59% |
| 2022 | 24.31 Billion DKK | 87.62% |
| 2021 | 12.96 Billion DKK | 347.39% |
| 2020 | 2.89 Billion DKK | -3.72% |
| 2019 | 3 Billion DKK | 0.0% |
| 2018 | - DKK | 0.0% |
| 2017 | - DKK | 0.0% |
| 2016 | - DKK | 0.0% |
| 2015 | - DKK | 0.0% |
| 2014 | - DKK | 0.0% |
| 2013 | - DKK | 0.0% |
| 2012 | - DKK | -100.0% |
| 2011 | 502 Million DKK | -0.4% |
| 2010 | 504 Million DKK | -48.04% |
| 2009 | 970 Million DKK | -1.45% |
| 2008 | 984.25 Million DKK | 2.37% |
| 2007 | 961.43 Million DKK | -18.2% |
| 2006 | 1.17 Billion DKK | -5.84% |
| 2005 | 1.24 Billion DKK | 4.33% |
| 2004 | 1.19 Billion DKK | 58.07% |
| 2003 | 756.82 Million DKK | -7.82% |
| 2002 | 821.01 Million DKK | -4.58% |
| 2001 | 860.46 Million DKK | -9.09% |
| 2000 | 946.5 Million DKK | -74.65% |
| 1999 | 3.73 Billion DKK | 103.47% |
| 1998 | 1.83 Billion DKK | 4.07% |
| 1997 | 1.76 Billion DKK | 86.39% |
| 1996 | 945.94 Million DKK | -28.4% |
| 1995 | 1.32 Billion DKK | -57.48% |
| 1994 | 3.1 Billion DKK | -7.07% |
| 1993 | 3.34 Billion DKK | 29.27% |
| 1992 | 2.58 Billion DKK | 50.94% |
| 1991 | 1.71 Billion DKK | 50.23% |
| 1990 | 1.14 Billion DKK | -27.06% |
| 1989 | 1.56 Billion DKK | 85.89% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 16.76 Billion DKK | 4.93% |
| 2024 Q2 | 51.6 Billion DKK | 207.85% |
| 2023 Q4 | 20.52 Billion DKK | 3.03% |
| 2023 Q3 | 19.92 Billion DKK | 2.62% |
| 2023 Q2 | 19.41 Billion DKK | -19.99% |
| 2023 FY | 20.52 Billion DKK | -15.59% |
| 2023 Q1 | 24.26 Billion DKK | -0.21% |
| 2022 Q4 | 24.31 Billion DKK | 0.75% |
| 2022 Q3 | 24.13 Billion DKK | -0.17% |
| 2022 Q2 | 24.17 Billion DKK | 0.39% |
| 2022 FY | 24.31 Billion DKK | 87.62% |
| 2022 Q1 | 24.08 Billion DKK | 85.82% |
| 2021 FY | 12.96 Billion DKK | 347.39% |
| 2021 Q1 | 2.83 Billion DKK | -2.24% |
| 2021 Q2 | 12.46 Billion DKK | 340.08% |
| 2021 Q3 | 12.39 Billion DKK | -0.52% |
| 2021 Q4 | 12.96 Billion DKK | 4.54% |
| 2020 Q1 | 2.86 Billion DKK | -4.75% |
| 2020 FY | 2.89 Billion DKK | -3.72% |
| 2020 Q3 | 2.63 Billion DKK | -3.62% |
| 2020 Q2 | 2.73 Billion DKK | -4.57% |
| 2020 Q4 | 2.89 Billion DKK | 9.9% |
| 2019 Q3 | 2.92 Billion DKK | -1.68% |
| 2019 Q4 | 3 Billion DKK | 2.8% |
| 2019 FY | 3 Billion DKK | 0.0% |
| 2019 Q1 | 3.2 Billion DKK | 0.0% |
| 2019 Q2 | 2.97 Billion DKK | -7.08% |
| 2018 Q2 | - DKK | 0.0% |
| 2018 FY | - DKK | 0.0% |
| 2018 Q3 | - DKK | 0.0% |
| 2018 Q1 | - DKK | 0.0% |
| 2018 Q4 | - DKK | 0.0% |
| 2017 Q1 | - DKK | 0.0% |
| 2017 Q3 | - DKK | 0.0% |
| 2017 FY | - DKK | 0.0% |
| 2017 Q4 | - DKK | 0.0% |
| 2017 Q2 | - DKK | 0.0% |
| 2016 Q2 | - DKK | 0.0% |
| 2016 Q4 | - DKK | 0.0% |
| 2016 Q1 | - DKK | 0.0% |
| 2016 Q3 | - DKK | 0.0% |
| 2016 FY | - DKK | 0.0% |
| 2015 FY | - DKK | 0.0% |
| 2015 Q2 | - DKK | 0.0% |
| 2015 Q1 | - DKK | 0.0% |
| 2015 Q4 | - DKK | 0.0% |
| 2015 Q3 | - DKK | 0.0% |
| 2014 Q2 | - DKK | 0.0% |
| 2014 FY | - DKK | 0.0% |
| 2014 Q4 | - DKK | 0.0% |
| 2014 Q3 | - DKK | 0.0% |
| 2014 Q1 | - DKK | 0.0% |
| 2013 FY | - DKK | 0.0% |
| 2013 Q1 | - DKK | 0.0% |
| 2013 Q4 | - DKK | 0.0% |
| 2013 Q3 | - DKK | 0.0% |
| 2013 Q2 | - DKK | 0.0% |
| 2012 Q3 | 503 Million DKK | 0.2% |
| 2012 Q4 | - DKK | -100.0% |
| 2012 Q2 | 502 Million DKK | -1.76% |
| 2012 FY | - DKK | -100.0% |
| 2012 Q1 | 511 Million DKK | 1.79% |
| 2011 Q4 | 502 Million DKK | 0.0% |
| 2011 FY | 502 Million DKK | -0.4% |
| 2011 Q1 | 504 Million DKK | 0.0% |
| 2011 Q2 | 504 Million DKK | 0.0% |
| 2011 Q3 | 502 Million DKK | -0.4% |
| 2010 Q1 | 968 Million DKK | -0.21% |
| 2010 Q2 | 1.01 Billion DKK | 5.17% |
| 2010 FY | 504 Million DKK | -48.04% |
| 2010 Q3 | 995 Million DKK | -2.26% |
| 2010 Q4 | 504 Million DKK | -49.35% |
| 2009 FY | 970 Million DKK | -1.45% |
| 2009 Q3 | 963 Million DKK | -1.63% |
| 2009 Q1 | 1.01 Billion DKK | 2.62% |
| 2009 Q2 | 979 Million DKK | -3.07% |
| 2009 Q4 | 970 Million DKK | 0.73% |
| 2008 Q3 | 974.34 Million DKK | 4.89% |
| 2008 Q4 | 984.25 Million DKK | 1.02% |
| 2008 Q2 | 928.9 Million DKK | -0.13% |
| 2008 Q1 | 930.12 Million DKK | -3.26% |
| 2008 FY | 984.25 Million DKK | 2.37% |
| 2007 Q2 | 1.16 Billion DKK | -0.97% |
| 2007 Q4 | 961.43 Million DKK | -15.17% |
| 2007 FY | 961.43 Million DKK | -18.2% |
| 2007 Q1 | 1.17 Billion DKK | -0.28% |
| 2007 Q3 | 1.13 Billion DKK | -2.35% |
| 2006 Q4 | 1.17 Billion DKK | -0.59% |
| 2006 Q3 | 1.18 Billion DKK | 0.26% |
| 2006 FY | 1.17 Billion DKK | -5.84% |
| 2006 Q2 | 1.17 Billion DKK | -3.26% |
| 2006 Q1 | 1.21 Billion DKK | -2.35% |
| 2005 Q2 | 1.26 Billion DKK | 1.66% |
| 2005 Q3 | 1.27 Billion DKK | 0.3% |
| 2005 Q4 | 1.24 Billion DKK | -1.84% |
| 2005 FY | 1.24 Billion DKK | 4.33% |
| 2005 Q1 | 1.24 Billion DKK | 4.25% |
| 2004 Q1 | 767.33 Million DKK | 1.39% |
| 2004 Q2 | 712.93 Million DKK | -7.09% |
| 2004 Q3 | 748.04 Million DKK | 4.92% |
| 2004 Q4 | 1.19 Billion DKK | 59.93% |
| 2004 FY | 1.19 Billion DKK | 58.07% |
| 2003 FY | 756.82 Million DKK | -7.82% |
| 2003 Q4 | 756.82 Million DKK | 0.0% |
| 2002 Q4 | 821.01 Million DKK | 0.0% |
| 2002 FY | 821.01 Million DKK | -4.58% |
| 2001 FY | 860.46 Million DKK | -9.09% |
| 2001 Q4 | 860.46 Million DKK | 0.0% |
| 2000 FY | 946.5 Million DKK | -74.65% |
| 2000 Q4 | 946.5 Million DKK | 0.0% |
| 1999 FY | 3.73 Billion DKK | 103.47% |
| 1999 Q4 | 3.73 Billion DKK | 0.0% |
| 1998 FY | 1.83 Billion DKK | 4.07% |
| 1998 Q4 | 1.83 Billion DKK | 0.0% |
| 1997 Q4 | 1.76 Billion DKK | 0.0% |
| 1997 FY | 1.76 Billion DKK | 86.39% |
| 1996 FY | 945.94 Million DKK | -28.4% |
| 1996 Q4 | 945.94 Million DKK | 0.0% |
| 1995 FY | 1.32 Billion DKK | -57.48% |
| 1995 Q4 | 1.32 Billion DKK | 0.0% |
| 1994 Q4 | 3.1 Billion DKK | 0.0% |
| 1994 FY | 3.1 Billion DKK | -7.07% |
| 1993 FY | 3.34 Billion DKK | 29.27% |
| 1993 Q4 | 3.34 Billion DKK | 0.0% |
| 1992 FY | 2.58 Billion DKK | 50.94% |
| 1992 Q4 | 2.58 Billion DKK | 0.0% |
| 1991 Q4 | 1.71 Billion DKK | 0.0% |
| 1991 FY | 1.71 Billion DKK | 50.23% |
| 1990 FY | 1.14 Billion DKK | -27.06% |
| 1990 Q4 | 1.14 Billion DKK | 0.0% |
| 1989 Q4 | 1.56 Billion DKK | 0.0% |
| 1989 FY | 1.56 Billion DKK | 85.89% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ALK-Abelló A/S | 439 Million DKK | -4576.082% |
| Bavarian Nordic A/S | 15.13 Million DKK | -135532.64% |
| Genmab A/S | 680 Million DKK | -2918.824% |
| Gubra A/S | 60.68 Million DKK | -33727.14% |
| Orphazyme A/S | - DKK | -Infinity% |
| Pharma Equity Group A/S | 8.07 Million DKK | -254211.199% |
| Zealand Pharma A/S | 102.57 Million DKK | -19912.674% |